First Posted 2018-07-03 Trial status Active, not recruiting Sponsor Groupe Oncologie Radiotherapie Tete et Cou Abstract Presentation NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details Press Release GORTEC Announces New Trial Suc

First Posted 2017-03-27 Trial status Active, not recruiting Sponsor Sarcoma Alliance for Research through Collaboration Abstract Presentation Meeting Abstract: 2024 ASCO Annual Meeting Sarcoma - May 29, 2024 SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. Click here for details Peer-reviewed journal publication THE LANCET Volume 404, Issue 10467p2053-2064November 23, 2024 Safety and efficacy of pembrolizuma